“Intravitreal Sirolimus for the Treatment of Geographic Atrophy: Results of a Phase I/II Clinical Trial”, Invest Ophthalmol Vis Sci, vol. 56, pp. 330-338, 2015.
, “Effect of Long-Chain ω-3 Fatty Acids and Lutein + Zeaxanthin Supplements on Cardiovascular Outcomes: Results of the Age-Related Eye Disease Study 2 (AREDS2) Randomized Clinical Trial”, JAMA Intern Med, vol. 174, pp. 763-771, 2014.
, “Spectral-Domain Optical Coherence Tomography Characteristics of Intermediate Age-Related Macular Degeneration”, Opthalmology, vol. 120, pp. 140-150, 2013.
, “Treatment of Geographic Atrophy with Subconjunctival Sirolimus: Results of a Phase I/II Clinical Trial”, Invest Ophthalmol Vis Sci, vol. 54, pp. 2941-2950, 2013.
, “Randomized, Placebo-Controlled Trial of Propranolol Added to Topiramate in Chronic Migraine”, Neurology, vol. 78, pp. 976-984, 2012.
, “Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine.”, Neurology, vol. 78, no. 13, pp. 976-84, 2012.
, “Treatment of Geographic Atrophy by the Topical Administration of OT-551: Results of a Phase II Clinical Trial”, Invest Ophthlmol Vis Sci, vol. 51, pp. 613-619, 2010.
, “Association of Cognitive Function and Depression with Age-Related Macular Degeneration in the Age-Related Eye Disease Study 2 (AREDS2)”, in Annual Meeting, Association for Research in Vision and Ophthalmology (ARVO), Fort Lauderdale, FL, 2009.
, “Improved Outcomes with Home-Based Administration of Palivizumab: Results from the 2000-2004 Palivizumab Outcomes Registry”, J Perinatol, vol. 28, pp. 511-517, 2008.
, “Prevention of Hospitalization Due to Respiratory Syncytial Virus: Results from the Palivizumab Outcomes Registry”, J Perinatol, vol. 28, pp. 511-517, 2008.
, “Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry.”, J Perinatol, vol. 28, no. 7, pp. 511-7, 2008.
,